Redmile Group, LLC
Q3 2026 13F-HR Holdings
Net value change ($000)
-123,257
(-8.3%)
New positions
6
Sold out positions
1
Turnover %
8.9%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q2 2026
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| NRIX | 88,505 | 89.6% |
| ELECTRA THERAPEUTICS INC | 61,098 | NEW |
| ATTOVIA THERAPEUTICS INC | 19,944 | NEW |
| ADARX PHARMACEUTICALS INC | 15,341 | NEW |
| OBSIDIAN THERAPEUTICS INC | 11,439 | NEW |
| TCGX ACQUISITION CORP | 3,751 | NEW |
| SLN | 3,129 | 13.2% |
| CBLL | 1,911 | 25.4% |
| OCUL | 1,871 | NEW |
| ADCT | 1,799 | 14.6% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|